Skip to Content
Radiation Research Program
Contact NExT
Show menu
Search this site
Last Updated: 09/24/18

Specialized Initiatives

Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC)

The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) is a collaborative (U01-funded) initiative that supports four individual research programs for in vivo and in vitro testing of investigational anti-tumor drugs as adjuvants to chemo-radiotherapy. (These agents are included in a list at Cancer Therapy Evaluation Program [CTEP] Agents and Active Agreements.) The PCRTC will develop a rigorous preclinical testing program for existing CTEP portfolio molecularly targeted agents, and newly acquired investigational agents when combined with radiation and systemic chemotherapy. The goal of the individual sub-programs is to generate reliable data that will be reproduced within the PCRTC and used for new agent prioritization decisions and to better inform clinical trial designs. This will enhance the likelihood of positive clinical trials that lead to more effective treatments for cancers treated with radiation.

Radiation and Nuclear Countermeasures Program

This is a program of the U.S. Department of Health and Human Services, Office of Public Health Emergency Medical Countermeasures, and the National Institutes of Health. The program is coordinated by NIAID, with the involvement of the National Cancer Institute. The Strategic Plan and Research Agenda is intended to unify and strengthen the radiation research community, promote increased collaboration, and facilitate transition from research to product development. NIH will work closely with HHS to prioritize the research and development activities in this ambitious agenda with the resources available and as one component of the larger national biodefense research agenda.

A Prospective Randomized Phase 3 Trial of Carbon Ion versus Conventional Radiation Therapy for Locally, Advanced, Unresectable Pancreatic Cancer

The overall objective of this Broad Agency Announcement (BAA) is to conduct a definitive randomized phase 3 clinical trial of carbon ion radiotherapy vs. 3D conformal radiation therapy for unresectable pancreatic cancer. The clinically relevant outcomes of this trial shall also be indirectly compared to those of parallel trial, RTOG1201, carried out by NRG Oncology, a member organization of the NCI Clinical Trials Network (NCTN).

Planning Guidance for Response to a Nuclear Detonation, 2nd Ed (PDF)

The Planning Guidance focuses on topics relevant to emergency planning within the first few days of nuclear detonation including: 1) shelter and evacuation, 2) medical care, and 3) population monitoring and decontamination. This guidance was developed by a Federal interagency committee led by the Executive Office of the President (National Security Staff and Office of Science and Technology Policy) with representatives from several federal U.S. Departments.

Quantitative Imaging for Response Assessment

Quantitative Imaging Network (QIN)

This network is one of several being conducted within the Cancer Imaging Program. It is designed to promote research and development of quantitative imaging methods for the measurement of tumor response to therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Projects include the appropriate development and adaptation/implementation of quantitative imaging methods, imaging protocols, and software solutions/tools (using existing commercial imaging platforms and instrumentation) and application of these methods in current and planned clinical therapy trials.

The Cancer Imaging Archive (TCIA)

The Cancer Imaging Archive (TCIA) is provided by the Cancer Imaging Program (CIP) as a service to the research community. TCIA provides a freely accessible, open archive of cancer-specific medical images and metadata accessible for public download. A huge amount of clinical and research images are collected each year with many high value data sets already available.